AR006202A1 - USES OF IGE ANTAGONIST TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF ALLERGIC DISEASES AND COMPOSITIONS CONTAINING THEM - Google Patents
USES OF IGE ANTAGONIST TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF ALLERGIC DISEASES AND COMPOSITIONS CONTAINING THEMInfo
- Publication number
- AR006202A1 AR006202A1 ARP970100986A ARP970100986A AR006202A1 AR 006202 A1 AR006202 A1 AR 006202A1 AR P970100986 A ARP970100986 A AR P970100986A AR P970100986 A ARP970100986 A AR P970100986A AR 006202 A1 AR006202 A1 AR 006202A1
- Authority
- AR
- Argentina
- Prior art keywords
- prepare
- treatment
- ige
- ige antagonist
- compositions containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Usos y composiciones de antagonista IgE para preparar un medicamento útil para el tratamiento de una enfermedad alérgica caracterizado por una cantidadefectiva de dicho antagonista IgE, que es administrado como: (a) una dosis de carga durante unperíodo de al menos alrededor de 14 días suficientes parareducir el nivel promedio de IgE libre en suero del paciente hasta un nivel no mayor de alrededor de 50ng/ml al final del período de carga; seguido por (b)una dosis de mantenimiento entrealre dedor de 8x10(5) hasta 2.4x10(3) mg/kg/semana del antagonista IgE para cada IU/ml línea de base IgE libre en elsuero del paciente.Uses and compositions of IgE antagonist to prepare a medicament useful for the treatment of an allergic disease characterized by a defective amount of said IgE antagonist, which is administered as: (a) a loading dose over a period of at least about 14 days sufficient to reduce the average level of free IgE in the patient's serum to a level no greater than about 50ng / ml at the end of the loading period; followed by (b) an interval maintenance dose of 8x10 (5) to 2.4x10 (3) mg / kg / week of the IgE antagonist for each IU / ml baseline free IgE in the patient's serum.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61422096A | 1996-03-12 | 1996-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR006202A1 true AR006202A1 (en) | 1999-08-11 |
Family
ID=24460327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970100986A AR006202A1 (en) | 1996-03-12 | 1997-03-12 | USES OF IGE ANTAGONIST TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF ALLERGIC DISEASES AND COMPOSITIONS CONTAINING THEM |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0904108A1 (en) |
JP (1) | JP2001505181A (en) |
AR (1) | AR006202A1 (en) |
AU (1) | AU726143B2 (en) |
CA (1) | CA2246427A1 (en) |
IL (1) | IL126113A0 (en) |
WO (1) | WO1997033616A1 (en) |
ZA (1) | ZA971607B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US7393529B2 (en) | 1998-04-09 | 2008-07-01 | Idexx Laboratories, Inc. | Methods and compositions for inhibiting binding of IgE to a high affinity receptor |
WO2001040264A2 (en) * | 1999-12-06 | 2001-06-07 | Panacea Pharmaceuticals, Llc. | Peptide antigens |
GB0016441D0 (en) | 2000-07-04 | 2000-08-23 | Pharmagene Lab Limited | Therapeutic method |
US6787524B2 (en) | 2000-09-22 | 2004-09-07 | Tanox, Inc. | CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies |
WO2002089615A2 (en) * | 2001-05-03 | 2002-11-14 | Novartis Ag | Anti-ige antibody to treat ocular allergies |
GB201610198D0 (en) * | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
CN114028569B (en) * | 2021-12-20 | 2023-04-28 | 中国医学科学院基础医学研究所 | Use of immunoglobulin IgE for diagnosis and/or treatment of hypertension |
CN114504644B (en) * | 2021-12-24 | 2024-02-13 | 北京大学第一医院 | Use of anti-IgE antibodies for the treatment of adenoid hypertrophy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5449760A (en) * | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
US4940715A (en) * | 1988-05-17 | 1990-07-10 | Kissei Pharmaceutical Co., Ltd. | 5H-pyrazolo[4,3-A] quinolizin-5-one compounds exhibiting therapeutic activities |
JP3156237B2 (en) * | 1991-12-24 | 2001-04-16 | 雪印乳業株式会社 | Anti-human IgE monoclonal antibody |
-
1997
- 1997-02-25 ZA ZA971607A patent/ZA971607B/en unknown
- 1997-03-06 JP JP53267597A patent/JP2001505181A/en active Pending
- 1997-03-06 IL IL12611397A patent/IL126113A0/en unknown
- 1997-03-06 AU AU19875/97A patent/AU726143B2/en not_active Ceased
- 1997-03-06 CA CA002246427A patent/CA2246427A1/en not_active Abandoned
- 1997-03-06 EP EP97908025A patent/EP0904108A1/en not_active Withdrawn
- 1997-03-06 WO PCT/US1997/003443 patent/WO1997033616A1/en not_active Application Discontinuation
- 1997-03-12 AR ARP970100986A patent/AR006202A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2246427A1 (en) | 1997-09-18 |
IL126113A0 (en) | 1999-05-09 |
EP0904108A1 (en) | 1999-03-31 |
WO1997033616A1 (en) | 1997-09-18 |
AU1987597A (en) | 1997-10-01 |
AU726143B2 (en) | 2000-11-02 |
JP2001505181A (en) | 2001-04-17 |
ZA971607B (en) | 1998-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69027216D1 (en) | TRANSMUCOSAL DOSAGE FORM | |
KR930702022A (en) | Treatment or prevention of type 1 diabetes by oral administration of insulin | |
ES2171469T3 (en) | COMPOSITION ADMINISTERED BY NASAL AND PREPARATION THAT CONTAINS IT. | |
PT88985A (en) | Process for the preparation of nasal and ophthalmic pharmaceutical compositions containing azelastine | |
DE69230112D1 (en) | ADVANCED DRUG DELIVERY SYSTEM AND METHOD FOR TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISEASES WITH CARBAMAZEPINE | |
ATE94393T1 (en) | DOSE FORM FOR ORAL ADMINISTRATION OF HYPOGLYCAEMIC GLIPICIDE. | |
KR101900520B1 (en) | A combination composition | |
ATE92762T1 (en) | MEDICATION. | |
MX173567B (en) | PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION TO IMPROVE THE SYMPTOMS OF HIV-INDUCED DISEASE OR REDUCE HIV TRANSCRIPTION AND PROLIFERATION | |
AU1935788A (en) | A process for producing an administration and/or dosage form for medically active ingredients of drugs | |
DK0412554T3 (en) | Sustained-release preparation for administration in the brain | |
ES2139842T3 (en) | USE OF MELATONIN TO TREAT PATIENTS WHO SUFFER DRUG DEPENDENCE. | |
AR006202A1 (en) | USES OF IGE ANTAGONIST TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF ALLERGIC DISEASES AND COMPOSITIONS CONTAINING THEM | |
RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
ES2119748T3 (en) | PHARMACEUTICAL COMPOSITION CONTAINING A PHARMACEUTICALLY SOLUBLE IN WATER. | |
KR890006227A (en) | Phenol-containing antitussive liquid composition | |
ES2115571T3 (en) | USE OF PENTOSANA POLISULFATE FOR THE RESOLUTION OF SCARS IN CHRONIC PROGRESSIVE VASCULAR DISEASES. | |
JPH01261334A (en) | Medical preparation containing angiotensine invertase inhibitor as effective component and production thereof | |
KR890004705A (en) | Antiviral agents | |
JPS6360940A (en) | Preventive or remedy for cataract | |
AR002727A1 (en) | THE USE OF RIDOGREL FOR THE MANUFACTURE OF A MEDICATION USEFUL FOR THE TREATMENT OF DIGESTIVE INFLAMMATORY DISEASES, A PHARMACEUTICAL COMPOSITION INCLUDING RIDOGREL AND A PROCEDURE FOR PREPARING SUCH COMPOSITION. | |
ES2038847T3 (en) | PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION CONTAINING ZIDOVUDINE AND INOSIPLEX FOR THE TREATMENT OF AIDS AND RELATED SYNDROMES. | |
ES2211594T3 (en) | MEDICATIONS CONTAINING PANTOTENIC ACID FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE ARTICULATIONS. | |
EP0402208B1 (en) | Mixture of Vitamin A in physiological dosis and different active ingredients having therapeutic effect | |
AR062894A1 (en) | FORMULATIONS FOR THERAPEUTIC ESTIMULATION HORMONE THERAPEUTIC ADMINISTRATION (THS) |